Health
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial – OncLive
Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Quality of life (QoL) according to patient-reported outcomes (PROs) was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib (Zejula) versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial, according to a subanalysis presented by Bhavana Pothuri, MD, during the ESMO 2020 Virtual Congress.
PRIMA was an ongoing a randomized, double-blind, placebo-controlled phase 3 trial in which patients with newly diagno…
-
Noosa News13 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News12 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News21 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News18 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up